Available Until 5/15/2023

Ambulatory Care Self-Assessment Program (ACSAP) Book 3: Neurologic Care and Pain Management (Cert # L229385)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 10/12/2022
Release Date: 11/15/2022
Expiration Dates: 05/15/2023
Activity Type: Application-based
CE Credits: 16 contact hours (BPS and ACPE)
Activity Fee: $80 (ASHP member); $120 (non-member) 

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 4 learning modules (see table below) and provides up to 16 contact hours of continuing pharmacy education and/or recertification credit. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ACCP and ASHP professional development program for BCACP recertification approved by the BPS. 

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

The target audience for Ambulatory Care Self-Assessment Program (ACSAP) Book 3: Neurologic Care and Pain Managementis board-certified and advanced level ambulatory care clinical pharmacists.

Board certified pharmacists are eligible to receive up to 16 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Contact Hours

Assessment Pass Point

Neurologic Care and Pain Management I

0217-9999-22-243-H01-P

3.5 ACPE/BPS

70%

Neurologic Care and Pain Management II

0217-9999-22-244-H01-P

4.5 ACPE/BPS

76%

Neurologic Care and Pain Management III

0217-9999-22-245-H01-P

3.5 ACPE/BPS

66%

Neurologic Care and Pain Management IV

0217-9999-22-246-H01-P

4.5 ACPE/BPS

72%

Neurologic Care and Pain Management I
ACPE Number: 0217-9999-22-243-H01-P
Attention-Deficit/Hyperactivity Disorder

  • Evaluate the signs and symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adults based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria.
  • Distinguish rating scales used for ADHD in children and adults.
  • Evaluate the most updated guideline recommendations for treating ADHD in children and adults.
  • Distinguish the treatment modalities for ADHD including nonpharmacologic and pharmacologic modalities.
  • Evaluate the acute and chronic adverse effects associated with stimulant and nonstimulant medications and strategies to minimize the adverse effects.
  • Synthesize a therapeutic regimen using appropriate agents for management of ADHD symptoms with appropriate goals of therapy.

Epilepsy in Adults

  • Classify seizures based on presentation and diagnostic considerations.
  • Evaluate an antiseizure medication regimen and develop a patient-specific monitoring plan for a patient with newly diagnosed epilepsy or with drug-resistant epilepsy.
  • Identify nonpharmacological treatment options for patients with drug-resistant epilepsy.
  • Assess treatment considerations of epilepsy in older adults and women.
  • Apply knowledge of comorbidities and patient-specific considerations common in people with epilepsy to the role of pharmacists.

Neurologic Care and Pain Management II
ACPE Number: 0217-9999-22-244-H01-P
Sleep-Wake Disorders

  • Develop a pharmacotherapy and monitoring plan for a patient with insomnia disorder according to recent guidelines and patient-specific characteristics.
  • Design an appropriate therapeutic plan for deprescribing benzodiazepines and non-benzodiazepine receptor agonists in patients using these agents for management of sleep-wake disorders.
  • Devise an appropriate pharmacotherapy and monitoring plan for the management of complications secondary to narcolepsy according to recent guidelines and patient-specific characteristics.
  • Justify appropriate screening, nonpharmacotherapy, pharmacotherapy, medication administration, and monitoring for patients with obstructive sleep apnea or narcolepsy according to recent guidelines and patient-specific characteristics.
  • Design appropriate pharmacotherapy and medication administration for patients with circadian rhythm sleep-wake disorders.
  • Develop a pharmacotherapy and monitoring plan for a patient with restless legs syndrome according to recent guidelines and patient-specific characteristics.

Multiple Sclerosis

  • Classify the variabilities in patient presentation and the multiple sclerosis (MS) disease course.
  • Analyze MS characteristics to distinguish the spectrum of MS and diagnostic subtypes.
  • Evaluate disease-modifying therapies for MS.
  • Apply knowledge of the MS subtypes and available MS treatments to select appropriate therapy.
  • Assess treatment considerations of MS in pediatric patients and during family planning and pregnancy.

Neurologic Care and Pain Management III
ACPE Number: 0217-9999-22-245-H01-P
Gabapentinoid Misuse

  • Evaluate current clinical evidence regarding the safety and efficacy of off-label use of gabapentinoids.
  • Analyze the physiologic basis for gabapentinoid clinical effects and misuse liability.
  • Evaluate the most common patterns of gabapentinoid misuse.
  • Analyze the current and changing regulatory status of gabapentinoids related to misuse.
  • Design strategies for recognizing and managing gabapentinoid misuse in ambulatory care pharmacy practice.

Opioid Overdose Prevention

  • Assess the role of outpatient pharmacists in preventing opioid-related harm.
  • Demonstrate the ability to ensure safe and appropriate patient and caregiver use of naloxone.
  • Distinguish key neurobiology factors of opioid use disorder and acute opioid overdose.
  • Apply the screening, brief intervention, and referral to treatment process to a patient case.
  • Devise a business plan for opioid overdose prevention considering the financial, legal, and ethical principles at play.
  • Demonstrate a patient-centered, non-stigmatizing approach to patient care and community education for opioid overdose prevention.

Neurologic Care and Pain Management IV
ACPE Number: 0217-9999-22-246-H01-P
Interactive Case: Statewide Tobacco Cessation Protocols

  • Assess current policy solutions involving pharmacists to address tobacco use.
  • Discover the process for creating a statewide tobacco cessation protocol, including forming connections with key stakeholders.
  • Develop a strategy for implementing a statewide tobacco cessation protocol in a pharmacy setting.
  • Devise a tobacco cessation treatment plan for a patient using a statewide tobacco cessation protocol.

Interactive Case: Migraine Headache

  • Assess the benefits and limitations of novel treatments for patients with migraine headaches.
  • Develop an appropriate treatment plan for an adult or pediatric patient with migraine headache, including acute treatment, prophylactic treatment, and patient education.
  • Justify drug therapy selection for migraine headache considering patient symptoms, comorbid conditions, and medication cost.
  • Design an appropriate treatment plan for a patient with medication overuse headache.

Interactive Case: Bias and Stigmatization in Substance Use Disorders

  • Analyze bias and stigmatization toward patients with substance use disorder.
  • Assess the impact of bias and stigmatization on the substance use disorder care continuum.
  • Evaluate mitigation strategies to reduce negative outcomes caused by bias and stigmatization in the care of patients with substance use disorder.

Series Editors

Brian K. Irons, Pharm.D., FCCP, BCACP
Professor
Jerry H. Hodge School of Pharmacy
Texas Tech University Health Sciences Center
Lubbock, Texas 

Ashley H. Meredith, Pharm.D., MPH, FCCP, BCACP, BCPS, CDCES
Clinical Professor of Pharmacy Practice
Purdue University
West Lafayette, Indiana

Faculty Panel Chair

Kirk E. Evoy, Pharm.D., BCACP, BC-ADM, CTTS
Clinical Associate Professor
Department of Pharmacotherapy
The University of Texas at Austin College of Pharmacy
San Antonio, Texas

Authors

Kelly C. Lee, Pharm.D., MAS, FCCP, BCPP
Professor of Clinical Pharmacy
Associate Dean, Assessment and Accreditation
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of California, San Diego
La Jolla, California 

Jamie Kneebusch, Pharm.D., BCPS, BCPP
Assistant Clinical Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of California, San Diego
La Jolla, California 

Sunita Dergalust, Pharm.D., BCPS
Clinical Pharmacy Specialist in Neurology and Neurosurgery
Program Manager in Neurology
Department of Pharmacy
VA Greater Los Angeles Healthcare System
Los Angeles, California 

Jacquelyn Louise Bainbridge, Pharm.D., BSPharm, FCCP, MSCS, FAES
Professor
Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Neurology, School of Medicine
University of Colorado, Anschutz Medical Campus
Aurora, Colorado 

Caitlin McCarthy, Pharm.D., BCPP
Clinical Assistant Professor
Department of Pharmacy Practice and Administration
Ernest Mario School of Pharmacy
Rutgers, the State University of New Jersey
Piscataway, New Jersey
Director of Pharmacy Services
Department of Pharmacy
Henry J. Austin Health Center
Trenton, New Jersey 

Ian R. McGrane, Pharm.D., BCPS, BCPP
Associate Professor
Department of Pharmacy Practice
University of Montana
Missoula, Montana 

Aimee M. Banks, Pharm.D., BCPS, MSCS
Clinical Pharmacist, Multiple Sclerosis
Pharmacy Clinical Team Lead, Neurology
Department of Specialty Pharmacy Services
Vanderbilt University Medical Center
Nashville, Tennessee 

Kirk E. Evoy, Pharm.D., BCACP, BC-ADM, CTTS
Clinical Associate Professor
Department of Pharmacotherapy
The University of Texas at Austin College of Pharmacy
San Antonio, Texas 

Jordan R. Covvey, Pharm.D., Ph.D., BCPS
Associate Professor of Pharmacy Administration
Division of Pharmaceutical, Administrative, and Social Sciences
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania 

Levi S. Campbell, Pharm.D.
Assistant Professor
Department of Pharmacy Practice
Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy
Amarillo, Texas 

Jennifer Ball, Pharm.D., BCACP, BCGP
Associate Professor
Department of Pharmacy Practice
South Dakota State University
Brookings, South Dakota
Adjunct Associate Professor
Department of Family Medicine
University of South Dakota
Vermillion, South Dakota 

Erin E. Miller, Pharm.D., MBA
Assistant Professor
Allied and Population Health
College of Pharmacy and Allied Health Professions
South Dakota State University
Sioux Falls, South Dakota 

Veronica P. Vernon, Pharm.D., BCPS, BCACP
Assistant Professor
Department of Pharmacy Practice
Butler University
Indianapolis, Indiana 

Deanna S. Kania, Pharm.D., BCPS, BCACP
Clinical Associate Professor of Pharmacy Practice
Purdue University
West Lafayette, Indiana
PGY1 Residency Program Director
Clinical Pharmacy Specialist, Ambulatory Care
Veteran Health Indiana
Indianapolis, Indiana 

Jennie B. Jarrett, Pharm.D., MMedEd, FCCP, BCPS
Assistant Professor
Department of Pharmacy Practice
University of Illinois Chicago
Chicago, Illinois 

Brianna M. McQuade, Pharm.D., MHPE, BCACP
Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois Chicago College of Pharmacy
Chicago, Illinois

Kelsey H. Blom, Pharm.D., BCACP
Clinical Pharmacy Specialist
Department of Neurology
Kaiser Permanente Northwest
Portland, Oregon 

Marcella R. Brown, Pharm.D., MPH, MS, BCACP, BCGP
Clinical Consultative Pharmacist
In-Patient Unit
Enclara Pharmacia, LLC
Philadelphia, Pennsylvania 

Jason Chau, Pharm.D., BCPS, BCACP, MSCS
Pharmacy Clinical Programs Coordinator
Department of Clinical Pharmacy Services
Kaiser Permanente
Renton, Washington 

Folayemi Fashola, Pharm.D., BCACP, MSCS
Drug Use Management Clinical Pharmacy Specialist
Department of Clinical Pharmacy
Kaiser Permanente Georgia
Atlanta, Georgia 

Thomas Franko, Pharm.D.
Associate Professor of Pharmacy Practice
Department of Pharmacy Practice
Nesbitt School of Pharmacy, Wilkes University
Wilkes Barre, Pennsylvania 

Meghan Haftman, Pharm.D., BCACP
Ambulatory Care Clinical Pharmacist
Ambulatory Clinical Pharmacy Services
Ascension Via Christi
Wichita, Kansas 

Lauren C. Haggerty, Pharm.D., BCACP
Assistant Professor and Director of Pharmacist Care Labs
Department of Clinical and Administrative Sciences
Notre Dame of Maryland University School of Pharmacy
Baltimore, Maryland 

Lucas G. Hill, Pharm.D., BCACP
Clinical Associate Professor
College of Pharmacy
The University of Texas at Austin
Austin, Texas 

Jason L. Isch, Pharm.D., BCACP
Assistant Professor
Department of Pharmacy Practice
Manchester University
Fort Wayne, Indiana
Clinical Ambulatory Care Pharmacist
Saint Joseph Health System
Mishawaka, Indiana 

Alison Knutson, Pharm.D., BCACP
Medication Management Pharmacist and Family Medicine Faculty
Department of Family Medicine and Community Health
Park Nicollet Health Services and University of Minnesota
St. Louis Park, Minnesota 

Brittany Johnson, Pharm.D., BCACP
Clinical Pharmacy Practitioner
Ambulatory Care
Hershel “Woody” Williams VAMC
Huntington, West Virginia 

Sarah E. Kubes, Pharm.D., BCPPS
Clinical Assistant Professor
College of Pharmacy, The University of Texas at Austin
Austin, Texas
Adjoint Assistant Professor
School of Medicine Department of Pediatrics, University
of Texas Health Science Center at San Antonio
General Pediatric Clinical Specialist Pharmacist
University Health System
San Antonio, Texas 

Sara Ly, Pharm.D., BCACP
Clinical Pharmacy Specialist
Department of Clinical Pharmacy
Kaiser Permanente Georgia
Atlanta, Georgia 

Sarah T. Melton, Pharm.D., FASCP, BCPP, BCACP
Professor of Pharmacy Practice
Department of Pharmacy Practice
Gatton College of Pharmacy at East Tennessee State University
Johnson City, Tennessee 

Tracey L. Mersfelder, Pharm.D., BCPS
Professor
Department of Pharmacy Practice
Ferris State University
Grand Rapids, Michigan 

Viet-Huong V. Nguyen, Pharm.D., BCCCP
Associate Professor (Neurology)
Department of Pharmacy Practice
Chapman University School of Pharmacy
Irvine, California
Clinical Pharmacist Specialist, Neurology and Critical Care
Department of Pharmacy Service
Harbor UCLA Medical Center
Torrance, California 

Jared Ostroff, Pharm.D., MBA, BCACP, BCGP
Ambulatory Pharmacy Supervisor
Baystate Health
Springfield, Massachusetts 

Melissa A. Pendoley, Pharm.D., BCACP
Geriatric and Palliative Care Clinical Pharmacy Specialist
Department of Pharmacy
Kaiser Permanente Georgia
Atlanta, Georgia 

Hanna Raber, Pharm.D., BCPS, BCACP
Assistant Professor (Clinical)
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, Utah 

Sarah Rajkovic, Pharm.D., MSCS
Clinical Pharmacist, Neurology
Department of Ambulatory Care Pharmacy Services
University of Colorado Hospital
Aurora, Colorado 

Katherine Montag Schafer, Pharm.D., BCACP, CDCES
Assistant Professor
Department of Family Medicine and Community Health
University of Minnesota
St. Paul, Minnesota 

Kimberly R. Schnacky, Pharm.D., BCPS, BCACP, DPLA
Clinical Pharmacy Program Manager—Non-Oncologic Biologics, Specialty Care and PACT
VISN 8 Pharmacy Benefits Management Clinical
Pharmacy Programs
Department of Veterans Affairs
Orlando, Florida 

Kyle V. Sheffer, Pharm.D., BCACP
Clinical Pharmacist
Department of Pharmacy
Santa Fe Indian Health Center, Indian Health Service, USPHS
Santa Fe, New Mexico

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, the American Society of Health-System Pharmacists (ASHP) and the American College of Clinical Pharmacy (ACCP) require that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity. 

Consultancies: Jacquelyn Louise Bainbridge (GW Pharma); Lucas Hill (Hikma Specialty); Brianna McQuade (Trevena)

Stock Ownership: Sara Ly (Johnson & Johnson); Melissa Pendoley (Eli Lilly)

Grants: Viet-Huong V. Nguyen (UCLA/Ionis Pharmaceuticals)

Note: All relevant financial relationships listed for these individuals have been mitigated.

All other planners, presenters, reviewers, ACCP and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on ambulatory care pharmacy activities.